Zbignew Wszolek, MD
Neurology · Jacksonville, FLNPI 1235128695
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,000 of the $13,798 with a category attached, or 94.2%. Eli Lilly accounts for 97.4% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $10,505 and has fallen 70.4% since, to $3,109 in 2024.
Across 9 payments — averaging $1533.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$13K
- Kyowa Kirin, Inc.$119
- Amneal Pharmaceuticals LLC$109
- Lundbeck LLC$65
- Acadia Pharmaceuticals Inc$64
Across 77 payments — averaging $7791.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$228K
- Biogen$217K
- Biohaven Pharmaceuticals, Inc.$66K
- Amylyx Pharmaceuticals, Inc.$52K
- Biohaven Pharmaceutical Holding Company Ltd.$37K
What the payments were for
- Consulting fees$13,00094%
- Travel & lodging$4413%
- Food & beverage$3583%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 5 | $13,441 |
| Kyowa Kirin, Inc. | 1 | $119 |
| Amneal Pharmaceuticals LLC | 1 | $109 |
| Lundbeck LLC | 1 | $65 |
| Acadia Pharmaceuticals Inc | 1 | $64 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,798 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 105 | $3,790 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 50 | $1,883 |
| Rasagiline Mesylate | 11 | $1,608 |
| Riluzole | 11 | $431 |
| Clonazepam | 13 | $224 |
| Trazodone Hcl | 15 | $56 |
Paid to pharmacies, not to this prescriber.
Other neurology in Jacksonville
- Steven ToenjesJacksonville$695K
- Zhigao HuangJacksonville$613K
- Kalina SandersJacksonville$544K
- Syed AsadJacksonville$302K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.